Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Is Combination Long-acting Beta-Agonist and Long-acting Muscarinic Antagonist Therapy the Future of COPD Therapy?

Alexander, Michael J. MD; Zappetti, Dana MD

doi: 10.1097/CPM.0000000000000181
Pulmonary Trends

Synopsis: A large, randomized, double-blind, multicenter, noninferiority trial revealed consistent superiority in exacerbation reduction, functional respiratory improvement, and quality-of-life indices in certain COPD patients treated with combination long-acting beta-agonist and long-acting muscarinic antagonist when compared with the standard long-acting beta-agonist and inhaled corticosteroid therapy that is commonly prescribed.

Reference: Wedzicha JA, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222–2234.

Disclosure: The authors declare that they have no conflicts of interest.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.